Epic Sciences ( Epic Sciences )

Epic Sciences

Epic Sciences's picture

Epic Sciences Inc. is a privately held biotech company that is developing highly sensitive diagnostic tests to molecularly characterize circulating tumor cells (CTCs) in the blood. We provide a better way to detect cancer and the ability to personalize and monitor cancer treatments.

Epic Sciences press release, blog etc

05/16/2018 - 14:42 Epic Sciences and Its Collaborators to Present New Data at ASCO 2018
02/08/2018 - 08:27 Epic Sciences to Present Single Cell PSMA Analysis to Provide Insight into Tumor Heterogeneity and Links to Response with Anti-PSMA Therapy
01/04/2018 - 14:04 Epic Sciences to Present at the 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit. Epic Sciences is one of six select companies chosen to present
01/04/2018 - 11:34 Epic Sciences to Present at the 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit.
01/04/2018 - 07:13 Epic Sciences to Present at the 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit
11/30/2017 - 13:09 Epic Sciences launches metastatic breast cancer circulating tumor cell panel.
11/30/2017 - 05:37 Epic Sciences Launches Metastatic Breast Cancer Circulating Tumor Cell Panel
11/02/2017 - 11:36 Epic Sciences launches single-cell microsatellite and chromosomal instability genomic analysis.
11/02/2017 - 05:11 Epic Sciences Launches Single-Cell Microsatellite and Chromosomal Instability Genomic Analysis
10/13/2017 - 10:20 Liquid biopsy test identifies androgen receptor protein expression in circulating tumor cells in women with metastatic breast cancer.
10/13/2017 - 07:45 Liquid Biopsy Test Identifies Androgen Receptor Protein Expression in Circulating Tumor Cells in Women with Metastatic Breast Cancer
09/06/2017 - 10:23 Liquid biopsy tumor heterogeneity test predicts resistance to targeted therapy in metastatic prostate cancer patients.
09/06/2017 - 04:45 Liquid Biopsy Tumor Heterogeneity Test Predicts Resistance to Targeted Therapy in Metastatic Prostate Cancer Patients
04/28/2017 - 06:40 Epic Sciences Announces Completion of $40 Million Series D Financing
01/05/2017 - 17:49 Results published in European Urology represent breakthrough in applying liquid biopsy to guide treatment decisions in prostate cancer
11/16/2016 - 12:15 Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer
11/16/2016 - 11:43 Liquid Biopsy Biomarker Identifies Patients with Improved Response to PARP Inhibition in Metastatic Castrate Resistant Prostate Cancer
10/31/2016 - 23:23 Epic Sciences Receives CAP Accreditation